Table 3.
Clinical manifestations of the patients with MIS-C according to age groups
| Total Patient | <5 years | 5-10 years | >10 years | P value | |
|---|---|---|---|---|---|
| Clinical Manifestations | n=36 (100%) | n=9 (25%) | n= 14(38.8%) | n=13 (36.1%) | X2 =0.05 |
| Severity of MIS-C | |||||
| Mild | 13 (36.1%) | 4 (44.4%) | 5 (35.7%) | 4 (30.7%) | 0.805 |
| Moderate | 6 (16.6%) | 2 (22.2%) | 3 (21.4%) | 1 (7.6%) | 0.554 |
| Severe | 17 (47.2%) | 3 (33.3%) | 6 (42.8%) | 8 (61.5%) | 0.392 |
| Clinical appearance | |||||
| Overlapping with KD | 25 (69.4%) | 6 (66.6%) | 12 (85.7%) | 7 (53.8%) | 0.396 |
| Overlapping with acute COVID-19 | 3 (8.3%) | - | 1 (7.1%) | 2 (15.3%) | 0.429 |
| Without overlapping with acute COVID-19 or KD | 8 (22.2%) | 3 (33.3%) | 1 (7.1%) | 4 (30.7%) | 0.219 |
| Mucocutaneous manifestation | 25 (69.4%) | 6 (66.6%) | 10 (71.4%) | 9 (69.2%) | 0.276 |
| Gastrointestinal manifestation | 24 (66.6%) | 4 (44.4%) | 8 (57.1%) | 12 (92.3%) | 0.04ഠ|
| Gastroenteritis | 10 (27.7%) | 2 (22.2%) | 3 (21.4%) | 5 (38.4%) | 0.560 |
| Hepatitis | 9 (25%) | 1 (11.1%) | 3 (21.4%) | 5 (38.4%) | 0.320 |
| Mesenteric lymphadenopathy | 5 (13.8%) | 1 (11.1%) | - | 4 (30.7%) | 0.011¥ |
| Ascites | 4 (11.1%) | - | 2 (14.2%) | 2 (15.3%) | 0.470 |
| Neurological manifestation | 14 (38.8%) | 4 (44.4%) | 6 (42.8%) | 4 (30.7%) | 0.752 |
| Headache | 3 (8.3%) | - | - | 3 (23%) | 0.055 |
| Agitation | 7 (19.4%) | 2 (22.2%) | 4 (28.5%) | 1 (7.6%) | 0.380 |
| Aseptic meningitis | 4 (11.1%) | 2 (22.2%) | 2 (14.2%) | - | 0.197 |
| Lung involvement | 3 (8.3%) | - | 1 (7.1%) | 2 (15.3%) | 0.214 |
| Parenchyma infiltration | 3 (8.3%) | - | 1 (7.1%) | 2 (15.3%) | 0.429 |
| Pleural effusion | 2 (%5.5) | - | - | 2 (15.3%) | 0.154 |
| Haematological involvement | 34 (94.4%) | 9 (100%) | 12 (85.7%) | 13 (100%) | 0.189 |
| Thrombocytopenia | 10 (27.7%) | 3 (33.3%) | 3 (21.4%) | 4 (30.7%) | 0.788 |
| Lymphopenia | 12(33.3%) | - | 6 (42.8%) | 6 (46.1%) | 0.049†‡ |
| D-dimer abnormality | 32 (88.8%) | 8 (88.8%) | 11 (78.5%) | 13 (100%) | 0.209 |
| Coagulation disorder | 10 (27.7%) | 1 (11.1%) | 4 (28.5%) | 5 (38.4%) | 0.308 |
| Prerenal insufficiency | 5 (13.8%) | 1 (11.1%) | 1 (7.1%) | 3 (23%) | 0.793 |
| Cardiac manifestations | 30 (83.3%) | 5 (88.8%) | 12 (85.7%) | 13 (76.9%) | 0.022‡ |
| Valve insufficiency | 25 (69.4%) | 5 (55.5%) | 9 (85.7%) | 11 (84.6) | 0.301 |
| Left ventricular dysfunction | 11(30.5%) | - | 3 (21.4%) | 8 (61.5%) | 0.01ഠ|
| Right ventricular dysfunction | 3 (8.3%) | - | - | 3 (23%) | 0.062 |
| Ventricular dilatation with normal EF | 5 (13.8%) | - | 3 (21.4%) | 2 (15.3%) | 0.343 |
| Coronary dilatation | 4 (11.1%) | 1 (7.1%) | 3 (23%) | 0.199 | |
| Pericardial effusion | 3 (8.3%) | - | 1 (7.1%) | 2 (15.3%) | 0.429 |
| ECG abnormality | 17 (47.2%) | 1 (11.1%) | 7 (50%) | 9 (69.2%) | 0.026‡ |
| Sinus tachycardia | 8 (22.2%) | 1 (11.1%) | 4 (28.5%) | 3 (23%) | 0.614 |
| Incomplete right bundle branch block | 5 (13.8%) | 1 (11.1%) | 2 (14.2%) | 2 (15.8%) | 0.959 |
| 1° AV block | 4 (11.1%) | - | 1 (7.1%) | 3 (23%) | 0.199 |
| ST elevation | 1 (2.7%) | - | - | 1 (7.6%) | 0.446 |
| Normal ECG rhythm | 19 (52.7%) | 8 (88.8%) | 7 (50%) | 4 (30.7%) | 0.026‡ |
| ICU | 4 (11.1%) | - | - | 4 (30.7%) | 0.553 |
| Vasoactive drugs | 11 (30.5%) | 4 (44.4%) | 3 (21.4%) | 4 (30.7%) | 0.505 |
| Mechanical ventilation | - | - | - | - | |
| ECMO | - | - | - | - | |
Categorical variables were presented as number and percentage. Age groups were compared with X2 test
†p < 0.05; < 5-year-old patients versus between 5- and 10-year-old patients
‡p < 0.05; > 10-year-old patients versus < 5-year-old patients
¥p < 0.05; > 10-year-old patients versus between 5- and 10-year-old patients